United Therapeutics (UTHR) Set to Announce Quarterly Earnings on Tuesday

United Therapeutics (NASDAQ:UTHR) is set to issue its quarterly earnings data before the market opens on Tuesday, February 20th. Analysts expect the company to announce earnings of $3.59 per share for the quarter.

United Therapeutics (NASDAQ:UTHR) opened at $129.50 on Tuesday. The firm has a market cap of $5,600.00, a price-to-earnings ratio of 11.42 and a beta of 1.26. United Therapeutics has a fifty-two week low of $112.01 and a fifty-two week high of $169.89.

UTHR has been the topic of a number of recent analyst reports. HC Wainwright restated a “hold” rating and set a $95.00 target price on shares of United Therapeutics in a report on Thursday, October 26th. Cowen restated a “hold” rating and set a $129.00 target price on shares of United Therapeutics in a report on Friday, October 27th. ValuEngine upgraded shares of United Therapeutics from a “hold” rating to a “buy” rating in a report on Thursday, November 30th. BidaskClub raised shares of United Therapeutics from a “sell” rating to a “hold” rating in a research report on Wednesday, December 6th. Finally, TheStreet raised shares of United Therapeutics from a “c+” rating to a “b” rating in a research report on Friday, December 15th. Four equities research analysts have rated the stock with a sell rating, five have assigned a hold rating and four have assigned a buy rating to the company’s stock. The stock has an average rating of “Hold” and an average target price of $140.27.

In other news, Director Christopher Causey sold 580 shares of the business’s stock in a transaction dated Thursday, December 7th. The shares were sold at an average price of $134.72, for a total value of $78,137.60. Following the completion of the sale, the director now owns 1,555 shares of the company’s stock, valued at $209,489.60. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Martine A. Rothblatt sold 1,241 shares of the business’s stock in a transaction dated Thursday, November 30th. The shares were sold at an average price of $128.95, for a total transaction of $160,026.95. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 10,136 shares of company stock valued at $1,248,989. Company insiders own 7.80% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “United Therapeutics (UTHR) Set to Announce Quarterly Earnings on Tuesday” was originally reported by American Banking News and is the sole property of of American Banking News. If you are reading this news story on another publication, it was stolen and reposted in violation of United States & international copyright laws. The original version of this news story can be accessed at https://www.americanbankingnews.com/2018/02/13/united-therapeutics-uthr-set-to-announce-quarterly-earnings-on-tuesday.html.

About United Therapeutics

United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. The Company markets and sells four commercial therapies in the United States to treat pulmonary arterial hypertension (PAH): Remodulin (treprostinil) Injection; Tyvaso (treprostinil) Inhalation Solution (Tyvaso); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca).

Earnings History for United Therapeutics (NASDAQ:UTHR)

Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply